552 related articles for article (PubMed ID: 27486880)
1. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
2. Lysosome-associated protein transmembrane-4β-35 is a novel independent prognostic factor in small cell lung cancer.
Qiao M; Hu G
Tumour Biol; 2015 Sep; 36(10):7493-9. PubMed ID: 25910706
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of LAPTM4B is correlated with tumor angiogenesis and poor prognosis in non-small cell lung cancer.
Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M
Med Oncol; 2014 Jun; 31(6):974. PubMed ID: 24816841
[TBL] [Abstract][Full Text] [Related]
4. LAPTM4B-35 overexpression is a risk factor for tumor recurrence and poor prognosis in hepatocellular carcinoma.
Yang H; Xiong FX; Lin M; Yang Y; Nie X; Zhou RL
J Cancer Res Clin Oncol; 2010 Feb; 136(2):275-81. PubMed ID: 19690886
[TBL] [Abstract][Full Text] [Related]
5. Significance of DEK overexpression for the prognostic evaluation of non-small cell lung carcinoma.
Liu X; Qi D; Qi J; Mao Z; Li X; Zhang J; Li J; Gao W
Oncol Rep; 2016 Jan; 35(1):155-62. PubMed ID: 26530274
[TBL] [Abstract][Full Text] [Related]
6. Predictive significance of combined LAPTM4B and VEGF expression in patients with cervical cancer.
Meng F; Tan S; Liu T; Song H; Lou G
Tumour Biol; 2016 Apr; 37(4):4849-55. PubMed ID: 26526574
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
8. LAPTM4B polymorphism is associated with non‑small cell lung cancer susceptibility and prognosis.
Tang H; Tian H; Yue W; Li L; Li S; Gao C; Si L; Qi L; Lu M; Hu W
Oncol Rep; 2014 May; 31(5):2454-60. PubMed ID: 24676601
[TBL] [Abstract][Full Text] [Related]
9. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of LAPTM4B: an independent prognostic marker in breast cancer.
Xiao M; Jia S; Wang H; Wang J; Huang Y; Li Z
J Cancer Res Clin Oncol; 2013 Apr; 139(4):661-7. PubMed ID: 23292099
[TBL] [Abstract][Full Text] [Related]
11. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of LAPTM4B, VEGF and survivin are correlated with tumor progression and poor prognosis in breast cancer patients.
Li S; Wang L; Meng Y; Chang Y; Xu J; Zhang Q
Oncotarget; 2017 Jun; 8(25):41282-41293. PubMed ID: 28476037
[TBL] [Abstract][Full Text] [Related]
13. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
14. LAPTM4B overexpression is a novel independent prognostic marker for metastatic ovarian tumors.
Yin M; Lou C; Zhang W; Meng F; Zhang H; Ning X; Zhou R; Dong X; Lou G
Int J Gynecol Cancer; 2012 Jan; 22(1):54-62. PubMed ID: 22193644
[TBL] [Abstract][Full Text] [Related]
15. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic features and prognostic implications of Gankyrin protein expression in non-small cell lung cancer.
Wang WP; Yan XL; Li WM; Ni YF; Zhao JB; Lu Q; Wang XJ; Sun Y; Chen P; Yan BY; Cui Y; Zhang ZP; Li XF
Pathol Res Pract; 2015 Dec; 211(12):939-47. PubMed ID: 26554593
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of LAPTM4B-35: a novel marker of poor prognosis of prostate cancer.
Zhang H; Wei Q; Liu R; Qi S; Liang P; Qi C; Wang A; Sheng B; Li L; Xu Y
PLoS One; 2014; 9(3):e91069. PubMed ID: 24651764
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer.
Gharabaghi MA
Clin Respir J; 2018 Feb; 12(2):633-638. PubMed ID: 27768839
[TBL] [Abstract][Full Text] [Related]
19. Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer.
Guo X; Li D; Wu Y; Chen Y; Zhou X; Wang X; Huang X; Li X; Yang H; Xing J
Lung Cancer; 2015 Feb; 87(2):162-8. PubMed ID: 25576295
[TBL] [Abstract][Full Text] [Related]
20. MiRNA-200a expression is inverse correlation with hepatocyte growth factor expression in stromal fibroblasts and its high expression predicts a good prognosis in patients with non-small cell lung cancer.
Chen Y; Du M; Wang J; Xing P; Zhang Y; Li F; Lu X
Oncotarget; 2016 Jul; 7(30):48432-48442. PubMed ID: 27374174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
